AKYLA/ Financials
MarketsScreenerFinancialsResearchChat
Equity / PHARMACEUTICAL PREPARATIONS
Longeveron Inc. Common Stock
XNAS · usd
SIC 2834 · PHARMACEUTICAL PREPARATIONS
FIGI BBG00YZ6JJN6
1.60▲ 0.01 (0.63%)
As of 2026-10-23
Price / Volume
Valuation
Market Cap
Enterprise Value
—
Trailing P/E
—
Price / Sales
EV / Revenue
—
EV / EBITDA
—
Financial Highlights
Revenue (TTM)
Net Income (TTM)
EBITDA
Diluted EPS (TTM)
EBITDA Margin
Net Debt
—
Trading Information
Previous Close
1.59
Day's Range
1.48 – 1.68
52-Week Range
0.48 – 7.60
Volume
64.4K
Avg Volume
138.8K
Share Statistics
Shares Outstanding
Employees
38
Exchange
XNAS
Listed
2021-02-12
Share count as of August 6, 2026

Longeveron Inc. Common Stock (LGVN) Financial Statements

View
Income Statement
Detail
Standard
Period
Quarterly
Loading Income Statement…
Key questions about Longeveron Inc. Common Stock (LGVN)
What is Longeveron Inc. Common Stock's Market Cap?
Longeveron Inc. Common Stock's Market Cap is $51.0M, based on as-reported figures from SEC (XBRL) filings.
What is Longeveron Inc. Common Stock's Price / Sales?
Longeveron Inc. Common Stock's Price / Sales is 43.0×, based on as-reported figures from SEC (XBRL) filings.
What is Longeveron Inc. Common Stock's Revenue (TTM)?
Longeveron Inc. Common Stock's Revenue (TTM) is $1.2M, based on as-reported figures from SEC (XBRL) filings.
What is Longeveron Inc. Common Stock's Net Income (TTM)?
Longeveron Inc. Common Stock's Net Income (TTM) is -$23.5M, based on as-reported figures from SEC (XBRL) filings.
What is Longeveron Inc. Common Stock's EBITDA?
Longeveron Inc. Common Stock's EBITDA is -$22.9M, based on as-reported figures from SEC (XBRL) filings.
What is Longeveron Inc. Common Stock's Diluted EPS (TTM)?
Longeveron Inc. Common Stock's Diluted EPS (TTM) is -0.74, based on as-reported figures from SEC (XBRL) filings.
What is Longeveron Inc. Common Stock's EBITDA Margin?
Longeveron Inc. Common Stock's EBITDA Margin is -1925.4%, based on as-reported figures from SEC (XBRL) filings.
Akyla / Financials · LGVNAs-filed SEC (XBRL) data
Showing the most recent year. Subscribe for full statement history.
Income Statement(in USD, except per-share data)
Source: Akyla.ai
Line ItemJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024Mar 31, 2024Dec 31, 2023Sep 30, 2023Jun 30, 2023Mar 31, 2023Dec 31, 2022Sep 30, 2022
Revenues
Total revenues
YoY growth-9.2%+4.5%-39.5%-82.3%
Cost of revenues
Gross profit
% of revenue63.4%66.3%70.4%91.2%
Operating expenses
General and administrative
Research and development
Total operating expenses
% of revenue2213.6%1266.1%1549.6%5427.0%
Loss from operations
% of revenue-2150.2%-1199.7%-1479.2%-5335.8%
Other income
Other income, net
Total other income, net
Net loss
% of revenue-2116.0%-1189.9%-1491.5%-5270.8%
Basic net loss per share—
Diluted net loss per share—